Study raises questions about prostate cancer therapies targeting IGF-1
Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor (IGF-1) to activate its target receptor could have unexpected results especially if a major tumor suppressor gene - p53 - is already compromised, according to new research by investigators at Fred Hutchinson Cancer Research Center.